-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, GOLSLKuhCFEdLnEfh5a+gt61QcuhIQSpfEGWgKCBjL3I9ckesWO7uyIdFzOR9ip6 ErWpukLcftmYCZ/2Sh6Mgg== 0000949699-05-000080.txt : 20051130 0000949699-05-000080.hdr.sgml : 20051130 20051130170719 ACCESSION NUMBER: 0000949699-05-000080 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20051130 ITEM INFORMATION: Other Events FILED AS OF DATE: 20051130 DATE AS OF CHANGE: 20051130 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PHARMACYCLICS INC CENTRAL INDEX KEY: 0000949699 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943148201 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-26658 FILM NUMBER: 051235258 BUSINESS ADDRESS: STREET 1: PHARMACYCLICS INC STREET 2: 995 E ARQUES AVE CITY: SUNNYVALE STATE: CA ZIP: 94085-4521 BUSINESS PHONE: 408 774 0330 MAIL ADDRESS: STREET 1: PHARMACYCLICS INC STREET 2: 995 E ARQUES AVE CITY: SUNNYVALE STATE: CA ZIP: 94085-4521 8-K 1 body8k.htm FORM 8-K 11302005 8K DOC

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549


FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

November 30, 2005

(Date of earliest event reported)


PHARMACYCLICS, INC.

(Exact name of registrant as specified in its charter)

Delaware
000-26658
94-3148201
 (State or other jurisdiction of incorporation)
 (Commission File Number)
(I.R.S. Employer Identification Number)

995 E. Arques Avenue
Sunnyvale, California 94085-4521
(408) 774-0330

(Address of principal executive offices including zip code and registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):

[  ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[  ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[  ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[  ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Item 8.01     Other Events

Timothy Whitten and Markus F. Renschler, M.D. have each established plans under Rule 10b5-1 of the Securities Exchange Act of 1934, as amended, for the trading of Pharmacyclics, Inc. common stock. Under his plan, Mr. Whitten intends to sell up to 85,125 shares of Pharmacyclics common stock in accordance with a prearranged trading schedule over a twelve-month period beginning in January 2006. Under his plan, Dr. Renschler intends to sell up to 35,000 shares of Pharmacyclics common stock in accordance with a prearranged trading schedule over the period of January 2006 through May 2006. Under both plans, the shares will be acquired pursuant to the exercise of vested stock options, which in the case of Dr. Renschler expire in January and May 2006, and sold on the open market at prevailing prices, provided that specified trading prices are achieved.

 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date:   November 30, 2005
  PHARMACYCLICS, INC.

By:           /s/ LEIV LEA   
Name:   Leiv Lea
Title:     Vice President, Finance & Administration
              and CFO and Secretary

 

 -----END PRIVACY-ENHANCED MESSAGE-----